Study on the mechanism of Astragalus-Panax notoginseng in the treatment of gastric ulcer based on network pharmacology

Abstract

Objective:To explore the possible mechanism of Astragalus Panax notoginseng in the treatment of GU by using network pharmacology. Methods: combined with the network pharmacology technology, the active components were obtained with the help of tcmsp database, OB≥30% and DL≥0.18 were set, the potential active components were screened, and the drug target information was obtained; After screening the genes, disenem and other important targets in the database; Using venny2 1 software, draw Wayne diagram and obtain drug disease common targets; Using Cytoscape 3.7.2 software, construct the "drug component target disease" network diagram, screen the core genes, and conduct go analysis and KEGG analysis. Results: 27 potential active components, 488 drug targets and 118 drug disease common targets were got. Go enrichment analysis showed that the intersection gene set was enriched to 1948 biological processes, 45 cell component expression processes and 106 processes related to molecular function. KEGG enrichment analysis is mainly based on 146 related signal pathways. The signal pathways of Astragalus Panax notoginseng in the treatment of Gu mainly involve proteoglycans in cancer, prostate cancer, EGFR tyrosine kinase inhibitor resistance and other signal pathways. Conclusion: Astragalus-Panax notoginseng drug pair can treat gastric ulcer through multiple components acting on multiple targets and multiple signal pathways, which preliminarily reveals its mechanism of action and provides a support for further empirical research.